A61K 47/6865
The tumour determinant being from skin, nerves or brain cancer cell
Official title: {the tumour determinant being from skin, nerves or brain cancer cell}
A61K47/6865 (The tumour determinant being from skin, nerves or brain cancer cell) appears on 192 US grants and 283 published applications in this corpus.
Search patents in A61K- Granted patents
- 192
- Published applications
- 283
- Assignees
- 137
- Inventors
- 456
- Latest grant
- 17 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 3 |
| 2003 | 0 | 3 |
| 2004 | 1 | 1 |
| 2005 | 0 | 6 |
| 2006 | 3 | 2 |
| 2007 | 1 | 4 |
| 2008 | 1 | 5 |
| 2009 | 1 | 3 |
| 2010 | 4 | 6 |
| 2011 | 2 | 4 |
| 2012 | 4 | 6 |
| 2013 | 6 | 6 |
| 2014 | 2 | 23 |
| 2015 | 16 | 13 |
| 2016 | 24 | 31 |
| 2017 | 25 | 34 |
| 2018 | 16 | 22 |
| 2019 | 20 | 16 |
| 2020 | 8 | 10 |
| 2021 | 15 | 21 |
| 2022 | 5 | 14 |
| 2023 | 10 | 13 |
| 2024 | 9 | 18 |
| 2025 | 7 | 16 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Interleukin-2 and use thereof17 Feb 2026US 12,551,531 B2Innovent Biologics (Suzhou) Co., Ltd.
- Targeting of multiple antigens with multiplex CAR T cells in solid and liquid malignancies11 Nov 2025US 12,466,869 B2Dana-Farber Cancer Institute, Inc.
- Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of glioblastoma28 Oct 2025US 12,453,762 B2Amal Therapeutics SA
- Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same30 Sep 2025US 12,428,477 B2Angiex, Inc.
- Immune antigen specific IL-18 immunocytokines and uses thereof12 Aug 2025US 12,383,631 B2Bright Peak Therapeutics AG
- Crosslinking antibodies10 Sep 2026US 2026/0263646 A1Enlaza Therapeutics, Inc.
- Melanoma targeting human antibodies and therapeutic uses thereof27 Aug 2026US 2026/0250415 A1Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - Irst S.R.L.
- Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity15 Jan 2026US 2026/0014140 A1Immunomedics, Inc.
- Anti-egfr/met antibodies and uses thereof18 Dec 2025US 2025/0382373 A1Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Antibodies specific to muc184 Dec 2025US 2025/0367313 A1Multitude Inc.
Most cited
By later US patents
- Anti-cancer drugs for the treatment of melanomas and method for preparing thereof173US 4,414,148 ASanofi · 1983
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009
- Auristatin drug linker conjugates82US 8,609,105 B2Seattle Genetics, Inc. · 2013
- Camptothecin-binding moiety conjugates76US 8,268,317 B2Immunomedics, Inc. · 2012
- Methods of treating acute myeloid leukemia by blocking CD4775US 8,562,997 B2The Board of Trustees of the Leland Stanford Junior University · 2013